Effect of hormone replacement therapy and calcitonin on bone mass in postmenopausal women

M. Meschia; M. Brincat; P. Barbacini; M. Carena Maini; R. Marri; P. G. Crosignani

doi:10.1016/0028-2243(92)90214-J

Effect of hormone replacement therapy and calcitonin on bone mass in postmenopausal women

M. Meschia, M. Brincat, P. Barbacini, M. Carena Maini, R. Marri, P. G. Crosignani

Fondazione IRCCS Ca' Granda- Ospedale Maggiore Policlinico

Research output: Contribution to journal › Article › peer-review

Abstract

A total of 104 postmenopausal women were randomly assigned to different therapeutic regimens: (a) calcitonin, (b) estrogen/progestogen (HRT) plus calcitonin, (c) estrogen/progestogen (HRT), (d) and the control group. The bone mass of the lumbar vertebrae of all patients was assessed with a dual beam photon absorptiometer (Norland GD 153). The 73 patients who completed the 1-yr study showed that postmenopausal bone loss could be prevented by either estrogen/progestogen (HRT) or calcitonin. In addition, the combination of hormonel replacement therapy and calcitonin not only prevented postmenopausal bone loss but resulted in a significant 10% gain in bone mass (P <0.001).

Original language	English
Pages (from-to)	53-57
Number of pages	5
Journal	European Journal of Obstetrics and Gynecology and Reproductive Biology
Volume	47
Issue number	1
DOIs	https://doi.org/10.1016/0028-2243(92)90214-J
Publication status	Published - Oct 23 1992

Keywords

Bone loss
Calcitonin
HRT

ASJC Scopus subject areas

Obstetrics and Gynaecology
Reproductive Medicine

Access to Document

10.1016/0028-2243(92)90214-J

Fingerprint Dive into the research topics of 'Effect of hormone replacement therapy and calcitonin on bone mass in postmenopausal women'. Together they form a unique fingerprint.

Cite this

@article{be50ca3bf9514cf8bd33952db4c1d9ba,

title = "Effect of hormone replacement therapy and calcitonin on bone mass in postmenopausal women",

abstract = "A total of 104 postmenopausal women were randomly assigned to different therapeutic regimens: (a) calcitonin, (b) estrogen/progestogen (HRT) plus calcitonin, (c) estrogen/progestogen (HRT), (d) and the control group. The bone mass of the lumbar vertebrae of all patients was assessed with a dual beam photon absorptiometer (Norland GD 153). The 73 patients who completed the 1-yr study showed that postmenopausal bone loss could be prevented by either estrogen/progestogen (HRT) or calcitonin. In addition, the combination of hormonel replacement therapy and calcitonin not only prevented postmenopausal bone loss but resulted in a significant 10% gain in bone mass (P <0.001).",

keywords = "Bone loss, Calcitonin, HRT",

author = "M. Meschia and M. Brincat and P. Barbacini and Maini, {M. Carena} and R. Marri and Crosignani, {P. G.}",

year = "1992",

month = oct,

day = "23",

doi = "10.1016/0028-2243(92)90214-J",

language = "English",

volume = "47",

pages = "53--57",

journal = "European Journal of Obstetrics, Gynecology and Reproductive Biology",

issn = "0028-2243",

publisher = "Elsevier Ireland Ltd",

number = "1",

}

TY - JOUR

T1 - Effect of hormone replacement therapy and calcitonin on bone mass in postmenopausal women

AU - Meschia, M.

AU - Brincat, M.

AU - Barbacini, P.

AU - Maini, M. Carena

AU - Marri, R.

AU - Crosignani, P. G.

PY - 1992/10/23

Y1 - 1992/10/23

N2 - A total of 104 postmenopausal women were randomly assigned to different therapeutic regimens: (a) calcitonin, (b) estrogen/progestogen (HRT) plus calcitonin, (c) estrogen/progestogen (HRT), (d) and the control group. The bone mass of the lumbar vertebrae of all patients was assessed with a dual beam photon absorptiometer (Norland GD 153). The 73 patients who completed the 1-yr study showed that postmenopausal bone loss could be prevented by either estrogen/progestogen (HRT) or calcitonin. In addition, the combination of hormonel replacement therapy and calcitonin not only prevented postmenopausal bone loss but resulted in a significant 10% gain in bone mass (P <0.001).

AB - A total of 104 postmenopausal women were randomly assigned to different therapeutic regimens: (a) calcitonin, (b) estrogen/progestogen (HRT) plus calcitonin, (c) estrogen/progestogen (HRT), (d) and the control group. The bone mass of the lumbar vertebrae of all patients was assessed with a dual beam photon absorptiometer (Norland GD 153). The 73 patients who completed the 1-yr study showed that postmenopausal bone loss could be prevented by either estrogen/progestogen (HRT) or calcitonin. In addition, the combination of hormonel replacement therapy and calcitonin not only prevented postmenopausal bone loss but resulted in a significant 10% gain in bone mass (P <0.001).

KW - Bone loss

KW - Calcitonin

KW - HRT

UR - http://www.scopus.com/inward/record.url?scp=0026488181&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026488181&partnerID=8YFLogxK

U2 - 10.1016/0028-2243(92)90214-J

DO - 10.1016/0028-2243(92)90214-J

M3 - Article

C2 - 1330761

AN - SCOPUS:0026488181

VL - 47

SP - 53

EP - 57

JO - European Journal of Obstetrics, Gynecology and Reproductive Biology

JF - European Journal of Obstetrics, Gynecology and Reproductive Biology

SN - 0028-2243

IS - 1

ER -

Effect of hormone replacement therapy and calcitonin on bone mass in postmenopausal women

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this